Authors

• Nitin Jain (ORCID: https://orcid.org/0000-0003-0114-8384)
• Michael J. Keating (ORCID: https://orcid.org/0000-0002-9121-6450)
• Alessandra Ferrajoli (ORCID: https://orcid.org/0000-0001-9547-4193)
• Patrick K. Reville (ORCID: https://orcid.org/0000-0001-8433-3360)
• Naveen Garg (ORCID: https://orcid.org/0000-0002-0321-2813)
• Sogand Sajedi (ORCID: https://orcid.org/0009-0008-4157-5579)
• Michael Richard Green (ORCID: https://orcid.org/0000-0001-6309-9472)
• Qing Deng (ORCID: https://orcid.org/0000-0001-5116-461X)
• Hussein A. Abbas (ORCID: https://orcid.org/0000-0003-2946-3562)
• William G. Wierda (ORCID: https://orcid.org/0000-0002-7357-270X)
• Jan A. Burger

Institutions

• The University of Texas MD Anderson Cancer Center (US)

Publication Details

Journal

Blood

Published

2024-11-05

DOI

https://doi.org/10.1182/blood-2024-206306

Primary Topic

Chronic Lymphocytic Leukemia Research

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• AstraZeneca
• Gilead Sciences
• F. Hoffmann-La Roche
• TG Therapeutics
• MEI Pharma
• CareDx
• Adaptive Biotechnologies
• BeiGene
• Incyte
• Servier
• Ipsen
• Genentech
• Pharmacyclics
• Juno Therapeutics
• Loxo Oncology